Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $110.0 million.

  • Nurix Therapeutics' Cash & Equivalents fell 20.80% to $78.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $78.4 million, marking a year-over-year decrease of 20.80%. This contributed to the annual value of $110.0 million for FY2024, which is 101.36% up from last year.
  • Per Nurix Therapeutics' latest filing, its Cash & Equivalents stood at $110.0 million for FY2024, which was up 101.36% from $54.6 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Cash & Equivalents registered a high of $119.4 million during FY2020, and its lowest value of $54.6 million during FY2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $64.5 million (2022), whereas its average is $76.4 million.
  • In the last 5 years, Nurix Therapeutics' Cash & Equivalents surged by 242.82% in 2020 and then slumped by 32.55% in 2021.
  • Over the past 5 years, Nurix Therapeutics' Cash & Equivalents (Yearly) stood at $119.4 million in 2020, then slumped by 32.55% to $80.5 million in 2021, then fell by 19.91% to $64.5 million in 2022, then dropped by 15.27% to $54.6 million in 2023, then surged by 101.36% to $110.0 million in 2024.